Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Chief Operating Officer Arthur Collins, 45, joins board of directors, filling a vacancy created by the retirement of company founder Earl Bakken, the company announces at its annual shareholders meeting on Aug. 31. Bakken, 70, will assume the title of founder and director emeritus. Collins, who previously worked at Abbott Labs, joined Medtronic as executive VP and President of Medtronic International in 1992 and was promoted to COO in January 1994. Collins also will serve as interim president of the Cardiac Surgery business beginning Oct. 1 in anticipation of the retirement of Senior Vice President and President-Cardiac Surgery Willard Lewis, 63, on Oct. 31. Lewis joined Medtronic in 1989 as VP and general manager-cardiopulmonary after having served first as a consultant during Medtronic's acquisition of Johnson & Johnson Cardiovascular in 1987

You may also be interested in...



99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   

UsernamePublicRestriction

Register

MT038090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel